期刊文献+

依托泊苷亚微乳在大鼠体内的药动学研究 被引量:2

Pharmacokinetic study of Etoposide Submicron Emulsion in rats
原文传递
导出
摘要 目的研究依托泊苷亚微乳在大鼠体内的药动学特征,并与依托泊苷注射剂比较。方法大鼠随机分为4组,每组6只,分别尾iv依托泊苷亚微乳2.5、5.0、10.0 mg/kg以及依托泊苷注射剂5 mg/kg,于给药后0.033、0.167、0.333、0.667、1、1.5、2、2.5、3、3.5、4、5、6 h取血。采用HPLC法测定大鼠全血中依托泊苷。结果大鼠iv依托泊苷亚微乳2.5、5、10 mg/kg后的药动学参数分别为t1/2:0.37、0.43、0.46 h;C0:4.72、8.7、15.5 mg/L;AUC0-t:1.57、2.84、6.21 mg·h/L。大鼠尾iv依托泊苷注射剂5 mg/L后的药动学参数分别为:t1/2为0.34 h,C0为7.53 mg/L,AUC0-t为2.63 mg·h/L。依托泊苷亚微乳给药剂量在2.5-10 mg时,t1/2无显著差异,C0、AUC0-t呈剂量相关性,符合线性药动学特点。与注射剂比较,依托泊苷亚微乳的t1/2延长,AUC增大。结论依托泊苷亚微乳的生物利用度有所提高,但半衰期仍然较短。 Objective To study the pharmacokinetic characteristics of Etoposide Submicron Emulsion in rats and compare with Etoposide Injection. Methods Rats were randomly divided into four groups, and each group had six rats. Etoposide Submicron Emulsion at doses of 2.5, 5, and 10 mg/kg and Etoposide Injection at dose of 5 mg/kg were iv administrated. Blood samples were collected at 0.033, 0.167, 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 h. Etoposide in rat whole blood were determined by HPLC method. Results Pharmacokinetic parameters of Etoposide Submicron Emulsion were as follows: t1/2 0.37, 0.43, and 0.46 h, C0 4.72, 8.7, and 15.5 mg/L, AUC0-t 1.57, 2.84, and 6.21 mg·h/L, respectively. And pharmacokinetic parameters of Etoposide Injection were as follows: t1/2 0.34 h, C0 7.53 mg/L, and AUC0-t 2.63 mg·h/L. There was no significant difference of t1/2 for Etoposide Submicron Emulsion at dosage from 2.5 to 10 mg, while C0 and AUC0-t were both dose dependent. Etoposide Submicron Emulsion presented a linear pharmacokinetic behavior. Compared with Etoposide Injection, AUC and t1/2 of Etoposide Submicron Emulsion increased. Conclusion Bioavailability of Etoposide Submicron Emulsion is improved, but half-life is still relatively short.
出处 《现代药物与临床》 CAS 2015年第8期938-942,共5页 Drugs & Clinic
关键词 依托泊苷亚微乳 依托泊苷注射剂 依托泊苷 血药浓度 药动学 Etoposide Submicron Emulsion Etoposide Injection etoposide blood concentration pharmacokinetics
  • 相关文献

参考文献10

  • 1Beijnen J H, Holthuis J J M, Kerkdijk H G, et al. Degradation kinetics of etoposide in aqueous solution[J].Int J Pharm Sci, 1988, 41(1/2): 169-178.
  • 2Smit E F, Camey D N, Harford P, et al. Phase II study of oral etoposide in ederly patients with small cell lung cancer[J].Thorax, 1989, 44(8): 257-263.
  • 3Hande K R. Etoposide: four decades of development of a topoisomerase II inhibitor[J].Eur J Cancer, 1998, 34(10): 1514-1521.
  • 4Sinkule J A. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent[J].Pharmacotherapy, 1984, 4(2): 61-73.
  • 5Shah J C, Chen J R, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide[J].Pharm Res, 1989, 6(5): 408-412.
  • 6Gao Z G, Choi H G, Shin H J, et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A[J].Int J Pharm, 1998, 161(1): 75-86.
  • 7Venkateswarlu V, Patlolla R R. Lipid microspheres as drug delivery systems[J].Ind J Pharm Sci, 2001, 63(6): 450-458.
  • 8M?ller R H, Schmidt S, Buttle I, et al. Sol Emulsl novel technology for the formulation of i.v. emulsions with poorly soluble drugs[J].Ind J Pharm Sci, 2004, 269(2): 293-302.
  • 9Chen H, Shi S, Zhao M M, et al. A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats[J].Drug Dev Ind Pharm, 2010, 36(12): 1444-1453.
  • 10李华龙,尹东东,王杏林.依托泊苷长循环亚微乳的制备和理化性质研究[J].现代药物与临床,2013,28(2):164-169. 被引量:6

二级参考文献4

  • 1Sinkule J A. Etoposide: a semisynthetic epipodophyllotoxin. chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent [J]. Pharmacotherapy, 1984, 4(2): 61-73.
  • 2Lundberg B B, Mortimer B C, Redgrave T (2 Submicron lipid emulsion containing amphipathic polyethylene.glycol for as drug-carriers with prolonged circulation time [J]. lnt J Pharm, 1996, 134(1/2): 119-127.
  • 3Shimada K, Miyagishima A, Sadzuka Y, et al. Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes [J]. J Drug Target, 1995, 3(4): 283-289.
  • 4Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles [J]. J Control Release, 2004, 95(3): 627-638.

共引文献5

同被引文献20

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部